CR20170020A - Variantes de proteínas de unión al factor h y métodos de uso de estas - Google Patents

Variantes de proteínas de unión al factor h y métodos de uso de estas

Info

Publication number
CR20170020A
CR20170020A CR20170020A CR20170020A CR20170020A CR 20170020 A CR20170020 A CR 20170020A CR 20170020 A CR20170020 A CR 20170020A CR 20170020 A CR20170020 A CR 20170020A CR 20170020 A CR20170020 A CR 20170020A
Authority
CR
Costa Rica
Prior art keywords
methods
factor
unions
variants
protein
Prior art date
Application number
CR20170020A
Other languages
English (en)
Inventor
Peter T Beernink
Original Assignee
Children´S Hospital & Res Center At Oakland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children´S Hospital & Res Center At Oakland filed Critical Children´S Hospital & Res Center At Oakland
Publication of CR20170020A publication Critical patent/CR20170020A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se brindan proteínas variantes de unión al factor H que pueden provocar anticuerpos bactericidas para al menos una cepa de Neisseria meningitidis, composiciones que comprenden dichas proteínas y métodos de uso de dichas proteínas.
CR20170020A 2014-07-23 2015-07-22 Variantes de proteínas de unión al factor h y métodos de uso de estas CR20170020A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462028123P 2014-07-23 2014-07-23
PCT/US2015/041616 WO2016014719A1 (en) 2014-07-23 2015-07-22 Factor h binding protein variants and methods of use thereof

Publications (1)

Publication Number Publication Date
CR20170020A true CR20170020A (es) 2017-08-10

Family

ID=55163727

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170020A CR20170020A (es) 2014-07-23 2015-07-22 Variantes de proteínas de unión al factor h y métodos de uso de estas

Country Status (15)

Country Link
US (10) US10266572B2 (es)
EP (2) EP3172224B1 (es)
JP (4) JP6796057B2 (es)
KR (2) KR102761870B1 (es)
CN (3) CN119613509A (es)
AU (5) AU2015292615B2 (es)
BR (1) BR112017001417B1 (es)
CA (2) CA2955802C (es)
CO (1) CO2017000558A2 (es)
CR (1) CR20170020A (es)
ES (1) ES2922554T3 (es)
MX (3) MX382409B (es)
NZ (2) NZ766005A (es)
RU (1) RU2714248C2 (es)
WO (1) WO2016014719A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122021020829B8 (pt) 2010-03-30 2022-12-27 Children´S Hospital & Res Center At Oakland Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
KR102761870B1 (ko) 2014-07-23 2025-02-05 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 인자 h 결합 단백질 변이체 및 이의 사용 방법
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
KR101855133B1 (ko) 2016-11-16 2018-05-08 주식회사 케이엠더블유 적층구조의 mimo 안테나 어셈블리
WO2018093176A2 (ko) 2016-11-16 2018-05-24 주식회사 케이엠더블유 적층구조의 mimo 안테나 어셈블리
AU2018379236B2 (en) * 2017-12-04 2025-02-27 Intravacc B.V. An improved process for producing outer membrane vesicles
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
GB202016604D0 (en) 2020-10-20 2020-12-02 Univ Of Oxford Compositions and methods for inducing an immune response
CA3211240A1 (en) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
WO1998052581A1 (en) 1997-05-20 1998-11-26 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
US20070026021A1 (en) 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
CN100379757C (zh) 1998-05-01 2008-04-09 希龙公司 脑膜炎奈瑟球菌抗原和组合物
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE122007000087I1 (de) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
KR100642044B1 (ko) 1999-03-19 2006-11-10 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
BR0014285A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
PL355163A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
AU2013206190A1 (en) 1999-11-29 2013-06-27 Novartis Vaccines And Diagnostics S.R.L. Compositions comprising Neisseria meningitidis antigens from serogroups B and C as well as a further antigen
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
ES2281409T3 (es) 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US6839862B2 (en) 2001-05-31 2005-01-04 Koninklijke Philips Electronics N.V. Parallel data communication having skew intolerant data groups
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
DK2353608T3 (da) * 2002-10-11 2020-02-10 Novartis Vaccines And Diagnostics S R L Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004074433A2 (en) 2003-01-30 2004-09-02 Yale University Rag polypeptides, nucleic acids, and their use
JP5173194B2 (ja) 2003-12-23 2013-03-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
SI2682126T1 (sl) 2005-01-27 2017-03-31 Children's Hospital & Research Center At Oakland Cepiva na osnovi veziklov, osnovanih na GNA1870, za širokospektralno zaščito proti boleznim, povzročenim z Neisserio meningitidisom
ZA200707420B (en) 2005-02-14 2009-04-29 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of age-related macular degeneration
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP2185576A4 (en) 2007-08-02 2011-01-12 Childrens Hosp & Res Ct Oak FHBP- AND LPXL1-BASED VESICIUM VACCINES FOR BROADBAND PROTECTION AGAINST NEISSERIA MENINGITIDIS-RELATED DISEASES
WO2009104097A2 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
AU2009223613B2 (en) 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
CN102203276A (zh) * 2008-08-27 2011-09-28 奥克兰儿童医院及研究中心 基于补体因子h对脑膜炎奈瑟球菌血清杀菌活性的鉴定
AU2009288095A1 (en) 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
WO2010127172A2 (en) 2009-04-30 2010-11-04 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) and methods of use
US20130022633A1 (en) 2009-10-27 2013-01-24 University Of Florence MENINGOCOCCAL fHBP POLYPEPTIDES
BR122021020829B8 (pt) * 2010-03-30 2022-12-27 Children´S Hospital & Res Center At Oakland Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
RU2546873C2 (ru) * 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
CN102028941B (zh) 2011-02-11 2013-02-13 中国医学科学院医学生物学研究所 一种b群脑膜炎球菌重组蛋白嵌合疫苗及其制备方法
RS57267B1 (sr) 2011-07-07 2018-08-31 De Staat Der Nederlanden Vert Door De Minister Van Vws Postupak za proizvodnju vezikula spoljašnje membrane gram-negativne bakterije bez upotrebe deterdženta
WO2013078223A1 (en) 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
MY167723A (en) * 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
GB201215005D0 (en) 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
BR112016002150A2 (pt) 2013-08-02 2017-09-12 Children´S Hospital & Res Center At Oakland proteínas de ligação de fator h de ocorrência natural (fhbp) e métodos de uso das mesmas
AU2015222121B2 (en) 2014-02-28 2018-01-18 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides
KR20150128099A (ko) 2014-05-08 2015-11-18 (주)엘지하우시스 Pla 및 pha 혼합수지를 이용한 벽지 및 그 제조 방법
CN104072590B (zh) * 2014-06-24 2017-08-25 上海生物制品研究所有限责任公司 一种脑膜炎球菌抗原组合及其应用
EP3169357B1 (en) * 2014-07-17 2018-11-07 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
KR102761870B1 (ko) 2014-07-23 2025-02-05 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 인자 h 결합 단백질 변이체 및 이의 사용 방법
EP3607967A1 (en) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides

Also Published As

Publication number Publication date
US12129282B2 (en) 2024-10-29
US10487122B2 (en) 2019-11-26
EP4074726A3 (en) 2022-11-23
US10266572B2 (en) 2019-04-23
AU2025202774A1 (en) 2025-05-08
RU2020105192A (ru) 2020-02-12
CN106715464A (zh) 2017-05-24
KR102761870B1 (ko) 2025-02-05
US20240101610A1 (en) 2024-03-28
KR102752259B1 (ko) 2025-01-13
AU2015292615B2 (en) 2019-10-24
AU2021203828B2 (en) 2023-04-13
CN119613509A (zh) 2025-03-14
US20250136648A1 (en) 2025-05-01
AU2023204391A1 (en) 2023-08-03
CA2955802A1 (en) 2016-01-28
AU2023204391B2 (en) 2025-01-23
RU2017104742A3 (es) 2019-02-27
US20250154206A1 (en) 2025-05-15
AU2019264600B2 (en) 2021-04-01
US20210101942A1 (en) 2021-04-08
US10995122B2 (en) 2021-05-04
BR112017001417A2 (pt) 2017-11-21
RU2714248C2 (ru) 2020-02-13
CA2955802C (en) 2023-10-31
JP2023011916A (ja) 2023-01-24
AU2025202774A9 (en) 2026-03-05
EP3172224A4 (en) 2018-04-18
RU2017104742A (ru) 2018-08-29
CN106715464B (zh) 2021-03-16
US20200095288A1 (en) 2020-03-26
MX382409B (es) 2025-03-13
US20190225655A1 (en) 2019-07-25
US20200109179A1 (en) 2020-04-09
MX2017001038A (es) 2018-02-09
JP2017522877A (ja) 2017-08-17
BR112017001417B1 (pt) 2023-11-07
US12269849B2 (en) 2025-04-08
AU2015292615A1 (en) 2017-03-16
US11834476B2 (en) 2023-12-05
US20170183384A1 (en) 2017-06-29
CO2017000558A2 (es) 2017-06-20
EP3172224B1 (en) 2022-06-29
NZ729206A (en) 2022-07-01
JP2021000121A (ja) 2021-01-07
EP3172224A1 (en) 2017-05-31
WO2016014719A1 (en) 2016-01-28
ES2922554T3 (es) 2022-09-16
AU2021203828A1 (en) 2021-07-08
NZ766005A (en) 2024-03-22
US20210340191A1 (en) 2021-11-04
JP7221917B2 (ja) 2023-02-14
CN112851768A (zh) 2021-05-28
JP2025108722A (ja) 2025-07-23
AU2019264600A1 (en) 2019-12-05
KR20230155595A (ko) 2023-11-10
JP6796057B2 (ja) 2020-12-02
NZ766444A (en) 2024-01-26
US10836799B2 (en) 2020-11-17
MX2021005373A (es) 2021-07-06
KR20170028442A (ko) 2017-03-13
JP7719046B2 (ja) 2025-08-05
NZ766003A (en) 2024-01-26
US20240025951A1 (en) 2024-01-25
US11673920B2 (en) 2023-06-13
EP4074726A2 (en) 2022-10-19
MX2023000204A (es) 2023-02-09
CA3212723A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
CR20170020A (es) Variantes de proteínas de unión al factor h y métodos de uso de estas
MX2020001270A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
SA519402159B1 (ar) بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
MX2017014136A (es) Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos.
CO2018005876A2 (es) Inmunoglobulinas conjugadas con lisina c-terminal
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
MX391159B (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
IL247221B (en) Antibodies binding dengue virus, compositions comprising same and uses thereof
BR112019012342A2 (pt) anticorpos il-11
EA201791485A1 (ru) Анти-cd47-антитела и их применения
BR112017001579A2 (pt) anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EP3256495A4 (en) Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
BR112017009764A2 (pt) anticorpos biespecíficos e métodos de uso em oftalmologia
BR112017023131A2 (pt) anticorpos anti- fcrn
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
EA201791716A1 (ru) Фармацевтический состав
EA201691493A1 (ru) Замещенные n-арилпиридиноны
MX385740B (es) Matrices de proteínas naturales reestructuradas.
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.